Head-to-Head: which pill tames hidradenitis suppurativa best?

NCT ID NCT07708480

Completed Disease control Sponsor: Hayat Abad Medical Complex, Peshawar Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study compares two oral drugs, apremilast and acitretin, to see which works better for moderate-to-severe hidradenitis suppurativa, a painful skin condition. About 70 adults take one of the two pills twice daily for 12 weeks. The main goal is to measure how much the disease severity improves.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral apremilast or oral acitretin
What this could lead to: If one drug proves more effective, it could offer a better treatment option for people with moderate-to-severe hidradenitis suppurativa.
What could go wrong: This is a small, 12-week trial, so results may not apply to all patients or predict long-term outcomes. Both drugs have potential side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIDRADENITIS SUPPURATIVA

Contacts and locations

Show contact details

Locations

Medical Teaching Institution-Lady Reading Hospital

Peshawar, Khyber Pakhtunkhwa, 26000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.